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Abstract
Background: To investigate the expression of E-cadherin, beta-catenin and topoisomerase-II alpha and examine
their clinical relevance in liposarcomas.
Materials and methods: The expression of E-cadherin, beta-catenin and topoisomerase II alpha was examined
immunohistochemically on formalin-fixed paraffin-embedded tissue specimens from 71 patients who underwent
surgical treatment for liposarcomas of the extremities or the retroperitoneum in two major cancer reference
centres between 1990 and 2000. Detailed medical notes were available for all patients who were followed for
median 82 months (range 5 to 215 months). Obtained expression data were weighted against clinical and
pathology parameters of clinical relevance.
Results: Patients were mostly male (59%), median age was 56 years for the liposarcomas of the extremities and 60
years for the retroperitoneal liposarcomas. The tumours were of diverse histology, grade and size (median
diameters 7 and 17 cm for tumours of the extremities and retroperitoneum respectively). Expression of b-catenin
protein was weakly detected in 15 cases (21.1%). Similarly weak expression of topoisomerase II-alpha was detected
in 14 (19.7%) cases of which only two had more than 20% of tumor cells stained positive. E-cadherin was not
detected in the studied cohort of liposarcomas. We did not detect associations between the expression of the
above proteins by liposarcoma cells and clinical outcome.
Conclusions: Liposarcomas do not express E-cadherin, which matches the absence of epithelioid differentiation in
this sarcoma subtype, and have low topoisomerase II-alpha expression, which justifies to some extend their
resistance to anthracycline-based chemotherapy.
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Background
Liposarcomas are the most common subtype of soft tis-
sue sarcomas (STS) accounting for approximately 20%
of all STS in adults [1,2]. The World Health Organiza-
tion Committee classifies them in 5 subtypes according
to the degree of differentiation [3]. Despite the fact that
each histological subtype has a different clinical behavior
and disease outcome, treatment is common for all lipo-
sarcoma subtypes and consists of wide resection of the
tumor followed by additional radiotherapy and occasion-
ally chemotherapy [4,5]. Although genetic tests have
emerged in liposarcomas, still limited data exist regard-
ing molecular profiling of these common STS subtypes
[6].
The expression of E-cadherin/beta-catenin complex
has been investigated in several tumors including STS
[7]. The E-cadherin/beta-catenin complex is formed at
cell-to-cell junctions and it is known to be involved in
the wingless/Wnt signal transduction pathway. Wnt
halts phosphorylation-degradation of the beta-catenin
protein, which is consecutively accumulated in the cyto-
plasm and translocated to the nucleus where it functions
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involved in cell proliferation [8,9]. Interestingly, reduced
expression of the E-cadherin/beta-catenin complex has
been associated with aggressive tumor features such as
poor differentiation, infiltrative growth, metastatic
potential and short patient survival in several cancer
types [10,11]. The DNA topoisomerase-II-alpha
(TOP2a) is one of the major nuclear proteins with peak
expression at G2/M phase. It is virtually involved in
every aspect of DNA metabolism, playing an important
role in chromosome organization and segregation [12].
This cellular molecule is considered a key modulator of
anticancer activity of anthracycline drugs [13,14].
In the present study we evaluated the expression of E-
cadherin, beta-catenin and TOP2a proteins in a series
of 71 liposarcoma cases and investigated potential asso-
ciations of these molecules with clinical outcome.
Methods
Formalin-fixed paraffin-embedded tissue specimens
from patients who had undergone surgical treatment for
liposarcomas for whom detailed medical notes and ade-
quate follow up records were made available, were
selected for this study.
Two co-author pathologists reviewed tumor speci-
mens, blinded to clinical information, at the Pathology
Department of the Ioannina University Hospital. (B.A.,
& P.I.) Histological typing was based on WHO classifi-
cation of soft tissue tumors.
Immunostaining was performed on formalin-fixed,
paraffin-embedded tissue sections using the EnVision
System (DAKO Corp, Netherlands), and the monoclo-
nal antibodies: E-cadherin (CM170B, Biocare Medical,
California), beta-catenin (DBS, Menarini, Hellas) and
DNA topoisomarase II-alpha (Ki-S1, DAKO). The
immunohistochemical (IHC) evaluations were per-
formed as previously described [15]. The evaluation of
IHC detected expression of E-cadherin, beta-catenin
and TOP2a was performed by a semiquantitative
method. The expression of each studied protein was
considered “weak” if 1% to 20% of cancer cells were
stained immunohistochemically, “moderate” if 21% to
50% were stained and “strong” if more than 50% of
cancer cells stained. Nuclear and cytoplasmic staining
for beta-catenin and TOP2a were evaluated separately.
Also, we included the intensity of staining in the clas-
sification of the each protein. Expression of each one
of the proteins was investigated for association with
clinical and pathological parameters, such as grade,
subtype, location, grade, surgical margins, relapse,
metastatic potential and overall survival. For the pur-
poses of the correlative analysis we used 20% stained
tumor cells as a cut-off level, above which, protein
expression was considered positive.
Statistical Analysis
The expression of E-cadherin, beta-catenin, TOP2a was
investigated for associations with various pathological
and clinical variables. Fisher’s test and Cox models esti-
mated hazard ratios were used to evaluate each candi-
date predictor. P values of < 0.05 were considered
statistically significant; all p values were two-tailed. All
the dates were calculated from the day of diagnosis. Sta-
tistical analyses were performed by using the Statistical
Program SPSS 14. (Chicago, IL, USA).
Results
Demographics
A total of 71 liposarcoma patients were included in the
study. The median age of patients was 56 years (range
20-86), and 42 were males (59%). Fifty-five liposarcomas
were located in the extremities, and 16 were retroperito-
neal. They had diverse histological liposarcoma subtypes.
In the extremities and the retropetinoneum the com-
monest histological subtype was the well differentiated.
In the extremities the commonest localization was the
thigh. (Figure 1c,d)
All patients received operation by different surgeons
on curative intent; surgical excision was performed in
the majority (68 patients) and 3 patients underwent
therapeutic limb amputation. Twenty-four patients had
positive surgical margins. All patients with positive sur-
gical margins (24) and others with marginal resection
and/or high grade characteristics were given adjuvant
postoperative therapy. In all, 47 patients received adju-
vant radiotherapy and 11 patients adjuvant chemother-
apy. Patient characteristics are presented in Table 1.
The median follow up of patients was 82 months (range
5 to 215 months). Within this follow-up period 54 patients
died. Thirty eight patients (53,5%) developed local recur-
rences and another 16, metastatic disease (22,5%). Patients
with retroperitoneal liposarcomas had higher local recur-
rence and death rates compared to those with tumor loca-
lization in the extremities (Table 1).
Expression of E-cadherin, beta-catenin and topoisomerase
II alpha (Table 2)
Immunostaining for E-cadherin was negative in all
cohort cases. Beta-catenin expression was documented
in 15 liposarcomas (27.3%). In 13 cases beta-catenin was
weakly expressed (1% to 10% stained tumor cells) (Fig-
ure 1b,c) and in 2 it was moderate (40% and 50% of
tumor cells stained) (Figure 1d). In the majority of cases
beta-catenin was found located at the membrane (12/
15). The intensity of beta-catenin was characterized
weak and moderate in 7 and 8 sarcomas, respectively.
TOP2a expression was detected in 14 cases. This was
moderate in 2 extremity liposarcomas (Figure 2a) and
weak in all other cases (Figure 2b). No strong TOP2a
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TOP2a, the molecule had nuclear location. The expres-
sion of the molecules in each subgroup (extremities, ret-
roperitoneum) is presented in Table 2. We did not
observe any statistically significant differences in the
expression of beta-catenin and TOP2a between the
extremities and the retroperitoneum (Table 2).
Clinicopathologic associations of beta-catenin and
topoisomerase II alpha
No correlation was found between expression of beta-
catenin or TOP2a and pathological factors, such as
tumor grade and histological subtype.
Beta-catenin (either membranous or nuclear expres-
sion) was not associated with local recurrences (p =
0.67), metastases (p = 0.47) or death (p = 0.47). Simi-
larly, TOP2a was not associated with clinical outcome
(p values of 0.52, 0.57 and 0.78 for local recurrences,
metastases and death, respectively). The cut-off level of
expression in more than 20% of tumor cells was used in
the pertinent analyses. However, different cut-off levels
were also utilized (i.e. any expression) with no change in
the results. Finally, similar results were obtained when
the analyses were performed separately in extremities
and retroperitoneal liposarcomas.
Discussion
Liposarcomas, is one of the commonest soft tissue sar-
comas, but have been poorly investigated regarding their
molecular profile. We evaluated the expression of E-cad-
herin, beta-catenin and TOP2a in a cohort of 71 lipo-
sarcoma cases and investigated for possible associations
with pathological characteristics and clinical outcome.
This is, to our knowledge, the largest study that investi-
gated E-cadherin, beta-catenin and topsiomerase II
alpha in liposarcomas.
We did not detect expression of E-cadherin in our
series, while 21% of cases were found to express beta-
catenin and 20% TOP2a. We consider that absence of
E-cadherin expression signifies the apparent mesenchy-
mal origin of liposarcomas and indicates lack of any
degree of epithelial differentiation in these tumors [7].
Similarly, other investigators have also reported lack of
expression of E-cadherin in smaller series of liposarco-
mas [7,16].
Regarding beta-catenin, few studies have investigated
its expression in liposarcomas. Ng et al., found only 2 of
31 liposarcomas with increased beta-catenin [17] and
Sakamoto et al., reported only cytoplasmic expression in
5 out of 12 studied cases [18]. However, none of these
studies reported membranous beta-catenin expression,
Figure 1 a) Retroperitoneal pleomorphic liposarcoma (H&E x400) b) Weak expression of beta-catenin in pleomorphic retroperitoneum
liposarcoma (< 20% of neoplastic cells showed cytoplasmic immunoreactivity (long arrow) and < 5% nuclear immunoreactivity (short
arrow) (DAB X400)). c) Weak expression of beta-catenin in extremity liposarcoma ((< 20% of neoplastic cells showed cytoplasmic
immunoreactivity (long arrow) and < 5% nuclear immunoreactivity (short arrow) (DAB x400). d) Area with extensive membranous and
cytoplasmic expression of beta-catenin in an extremity liposarcoma ((< 50% of neoplastic cells showed cytoplasmic and membranous
immunoreactivity (long arrow) (DAB x400)).
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(4.2%) had weak expression of beta-catenin localized in
the nucleus and 15% in the membrane. Although mem-
branous beta-catenin expression was detected in only a
small percentage of studied cohort this is still higher
than the percentage reported in previous studies. This
finding indicate that some liposarcomas may utilize at
least in part beta-catenin cell to cell adhesion. Nuclear
accumulation of beta-catenin is known to be involved in
the Wnt signalling pathway and interplay of these two
proteins have been implicated in several human carcers
and in aggressive synovial sarcomas [19,20]. However
this usually involves strong nuclear expression, which
was not the case in our series [20]. A major finding in
our study was the predominately membranous localiza-
tion of beta-catenin, which among STS has only been
described in uterine leiomyosarcomas [21]. Since,
membranous beta-catenin expression was low, if any, in
our liposarcomas, definite conclusion about its associa-
tion with the low metastatic potential of the majority of
these tumors can not be drawn [22,23].
The investigation of TOP2a in sarcomas has already
drawn the attention of several investigators and our
group [15,24]. This is due to its significant biologic role
in regulating DNA metabolism and function and also
because this enzyme is the target of the anthracyclin
doxorubicin, which is the main chemotherapy drug with
activity in sarcomas. The presence of TOP2a is consid-
ered a prerequisite for anthracyclins to exert their cyto-
toxic effects given that the activity of these drugs
correlates the nuclear content of the enzyme [14,25]. In
addition high expression of TOP2a has been profilied as
an indicator of tumor aggressiveness and poor outcome
in several tumor types [26].
Table 1 Demographics (percentages were calculated separately in each category)
EXTREMITIES (N = 55) RETROPERITONEUM (N = 16)
Age: median (range) 56 (31-80 years) 64 (37-86 years)
N Males (%) 32(58%) 10(63%)
Median Size in mm (range) 70.0 (7-280) 170.0 (35-500)
Location (%)
Thigh 27 (49%) -
Trunk 14 (26%) -
Leg 6 (11%) -
Arm 4 (7%) -
Forearm 3 (5%) -
Hand 1 (2%) -
Retroperitoneum - 16 (100%)
Histological subtype (%)
Well-differantiated liposarcomas with myxoid stroma 32 (58%) 10 (62%)
Pleomorhic 19 (35%) 1 (7%)
Round cell 2 (3%) 2 (12%)
Sclerosing well-differentiated 1(2%) 2 (12%)
Well-differentiated Lipoma-like/adipocyticliposarcoma 1 (2%) 1 (7%)
Grade
I (low) 38 (69%) 12 (75%)
II-III (High) 17 (31%) 4 (25%)
Type of surgery N (%)
Surgical excision 52(94%) 16(100%)
Amputation 3(6%) 0(0%)
Surgical Margins
Positive 16 (29%) 8(50%)
Negative 39 (71%) 8(50%)
Chemotherapy
Yes 7(12%) 4(25%)
No 48(88%) 12(75%)
Radiotherapy
Yes 36(66%) 11(69%)
No 19(34%) 5(31%)
Median total radiation dose (range) 57.0 Gy (20.0-64.0) 40.0 Gy (40.0-64.0)
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TOP2a to be intensively expressed in cell contours in
mature adipocytes and lipoblasts in all benign and
malignant lipomatous tumors, which led them suggest
that membranous immunostaining for TOP2a might be
a useful marker for diagnosing liposarcoma [27]. How-
ever we did not detect membranous localisation of
TOP2a but only weak nuclear expression. We consider
that faint nuclear TOP2a expression in our series
associates well to the limited activity of anthracyclins in
liposarcomas and also the relatively favourable prognosis
of this sarcoma subtype which still remains dismal
[5,28].
Conclusion
Profiling of the expression of three studied molecules in
this study elucidates to some extent some key clinical
aspects of liposarcomas: lack of E-cadherin expression
verifies the mesenchymal origin and weak beta-catenin
and TOP2a expression provide molecular reasoning of
the limited aggressiveness and marginal chemosensitivity
of these tumours.
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